The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Limitations in genetic testing for lung cancer
Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK, provides an overview of challenges clinicians face in gene testing for actionable mutations in the UK. Whilst genetic testing is offered to all patients with severe lung cancer regardless of age or smoking status, the quality of tissue remains inconsistent and the median time to process the tissue can be up to 19 days. Expediting the processing time is necessary to provide the best treatment options for patients. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Dr Navani has received honoraria for speaking, advisory boards or travel support from Amgen, Aidence, Astra Zeneca, Lilly, Takeda, Janssen, Merck, MSD, Pfizer, Oncimmune, PeerVoice, OncLive, Bristol-Meyers-Squibb and Olympus, as well as educational grants from Olympus, Cook Medical, Hitachi and Pentax.
